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Summary
Objective: Acute bacterial rhinosinusitis, which is a major health problem, is treated with
antibiotics. We developed a mouse model of acute bacterial rhinosinusitis to gain a better
understanding of the pathophysiology of the disease. Our goal was to investigate the response to
acute rhinosinusitis when treated with either a bactericidal or a bacteriostatic antibiotic.
Methods: C57BL/6 mice were infected intranasally with Streptococcus pneumoniae. One day
after inoculation, the mice were treated with either moxifloxacin (bactericidal) or azithromycin
(bacteriostatic). Different groups were euthanized during the first five days post-inoculation.
Bacterial counts from nasal lavage culture and the cell markers GR1, CD11b, CD3, CD4, and CD8 in
sinus tissue were evaluated by flow cytometry.
Results: Azithromycin led to rapid clearance of the bacteria and of the inflammation in contrast
to placebo. Surprisingly, moxifloxacin showed a limited effect. Investigations of this limited
effect of moxifloxacin suggested a high metabolic clearance, a low concentration at the site of
infection, and low persistent post-antibiotic effects of moxifloxacin in mice.
Conclusion: Our animal model of acute sinusitis has great utility for studying the disease, but the
difference between mice and man must always be considered in making extrapolations from
animal experiments to the human experience.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Corresponding author. Tel.: +1 773 702 0080; fax: +1 773 702 9813.
E-mail address: rnacleri@surgery.bsd.uchicago.edu
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Acute sinusitis, an inflammation of the lining membrane of
any of the paranasal sinuses, affects millions of people.
Acute sinusitis frequently follows a viral upper respiratory
tract infection and involves the maxillary sinus. Thus, if the
average American has four viral colds per year, and 1% ofPublished by Elsevier Ltd. All rights reserved.
402 T. Luxameechanporn et al.colds lead to acute sinusitis, then there are about 10 million
episodes of acute sinusitis in the USA each year.1 In approxi-
mately 60% of patients with acute maxillary sinusitis, bac-
teria can be isolated from amaxillary sinus aspirate, themost
common organism being Streptococcus pneumoniae. Epi-
sodes of acute bacterial rhinosinusitis are usually treated
with antibiotics. Thus, each year, millions of prescriptions are
written for the treatment of acute bacterial rhinosinusitis.2
Despite the magnitude of the problem, many questions
remain as to how best to treat an acute episode.
Antimicrobial drugs have been classified on the basis of
their action in vitro as being either bactericidal or bacterio-
static. For bactericidal drugs, theminimal bactericidal (MBC)
or lethal concentration is close to or identical to the minimal
inhibitory concentration (MIC). For bacteriostatic drugs, lit-
tle if any killing occurs at the MIC; only bacteriostasis occurs,
which is reversed on removal of the chemotherapeutic agent.
This distinction is blurred in vivo because bacteria whose
multiplication has been arrested by bacteriostatic drugs can
be killed by the cellular and humoral immune defenses of the
host. Moxifloxacin, an 8-methoxy quinolone, exerts a bacter-
icidal effect on S. pneumoniae by inhibiting the type II
topoisomerases, DNA gyrase and topoisomerase IV,3 whereas
azithromycin, a 15-membered-ring macrolide, inhibits bac-
terial protein synthesis by binding to two sites on the bacter-
ial 50 S ribosome (domains II and V), which causes dissociation
of transfer RNA and termination of peptide linking. Macro-
lides are classified as bacteriostatic for most Gram-positive
bacteria, in particular streptococci.
We previously developed a mouse model of acute bacter-
ial rhinosinusitis after intranasal inoculation with S. pneu-
moniae4,5 that mimics the disease in man.4,6 Our objective in
this study was to determine whether treatment of acute
bacterial rhinosinusitis caused by S. pneumoniae with a
bactericidal drug (moxifloxacin) compared to a bacterio-
static drug (azithromycin) caused less infection and more
rapid resolution of the inflammation.
Materials and methods
Experimental animals
Pathogen-free 6- to 8-week-old C57BL/6 mice of either sex
were purchased from Jackson Laboratories (Bar Harbor, ME,
USA). The animals were kept in microisolator cages in a
pathogen-free environment. Each group of animals was kept
isolated from the other groups in a biohazard containment
facility. All animals were used in protocols approved by the
Animal Care and Use Committee of the University of Chicago.
Antibiotic administration
Antibiotics were administered via 200 mL gavage. The doses
of moxifloxacin and azithromycin were 100 mg/kg and
200 mg/kg, respectively. The control group was administered
the sterile water diluent alone. The regimens were given
twice daily or four times daily, depending on the experiment.
Antibiotic serum levels
The pharmacokinetics of moxifloxacin (Bayer Corporation,
West Haven, CT, USA) and of azithromycin (Pfizer Labora-tories, Groton, CT, USA) were tested in the serum of mice.
Blood was drawn from the orbital sinus of mice at 0.5, 1, 2,
and 4 h after antibiotic dosing. The blood was centrifuged,
and the serum was collected. Ten microliters of serum were
then aliquoted onto sheep blood agar plates coated with S.
pneumoniae. The plates were incubated for 24 h at 37 8C,
after which zones of inhibition were measured. A standard
curve was formed by use of the known concentrations of the
antibiotics. Quantitative values were determined by extra-
polation from the standard curve.
Pharmacokinetic analyses were performed. Parameters
were defined as follows: Cmax was the maximal concentration
or activity observed; Tmax corresponded to the time that the
peakwas observed;T1/2, or half-life,was determined from the
elimination rate constant as calculated by linear regression
analysis fromTmax to the last time point. Area under the time—
concentration curves (AUCs) over 12 h (AUC0—12) were calcu-
lated by use of the trapezoidal rule; AUC0—24 was defined as
twice the AUC0—12. The 24-h AUC/MIC ratios were calculated
by dividing the AUC0—24 by the MIC for the specific drug.
Infection
S. pneumoniae (ATCC 49619) was used for induction of acute
sinusitis, as described previously.4,5 The strain used is anti-
genically similar to type 19 S. pneumoniae, the most common
strain cultured from human sinuses.4 The MICs of azithromy-
cin and moxifloxacin for this strain were 0.25 mg/mL.
S. pneumoniae was grown on blood agar plates, and
colonies were suspended in sterile saline solution immedi-
ately before inoculation of the mice. A turbidity equivalent
to McFarland no. 3 was used, which corresponds to approxi-
mately 1.2  109 colony-forming units per milliliter. Twenty-
five microliters of suspension S. pneumoniae were placed in
each nostril. Because mice are obligatory nasal breathers,
the fluid was drawn into the nasal passage during inhalation.
Nasal cultures
Mice were sedated and nasal lavage was performed with
200 mL of phosphate buffered saline (PBS). The lavage liquid
was then serially diluted (neat, 1:10, 1:100, 1:1000, and
1:10 000) and, at each dilution, plated onto Columbia sheep
blood agar plates. The plates were incubated for 48 h and
then counted. The results were quantified as colony-forming
units per milliliter (CFU/mL).
Tissue harvesting and processing
Flow-cytometric analysis was used for quantifying cells pre-
sent in the sinuses. The mice were euthanized, and the
spleen was harvested as a positive control. We removed
the skin and tissue from the head and then sagittally bisected
the skull, exposing the sinuses. The tissue from the sinuses
was removed manually. The harvested tissue was placed in
2 mL of PBS. We added 2 mL of PBS to 2 mg/mL collagenase P
(Roche Diagnostics, IN, USA) to give a final concentration of
1 mg/mL. The tissue was incubated at 37 8C for 1 h in a water
bath shaker. After tissue degradation, the suspension was
passed through a Nytex filter (Sefar-America Inc, NY, USA)
and the cells recovered in Dulbecco’s minimum essential
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Figure 1 Numbers of bacteria recovered from nasal lavage
culture 2—5 days after infection with S. pneumoniae. Mice were
treated with 12-hourly doses of 100 mg/kg moxifloxacin, 200 mg/
kg azithromycin, or sterile water (control). Horizontal bar repre-
sents mean value. The numbers of bacteria in the azithromycin-
treated mice decreased significantly in comparison with the mox-
ifloxacin-treated or control groups (*p < 0.05, **p < 0.01).
Figure 2 Bacterial counts in nasal lavage culture at day 4 post-
infection in mice treated with 12-hourly doses of 100 mg/kg
moxifloxacin and sterile water (control). Samples were collected
1 h and 3 h post-dosing of moxifloxacin and 3 h post-dosing of
sterile water. Horizontal bar represents mean value. There was a
significant decrease in the numbers of bacterial counts in mice
treated with moxifloxacin 1 h and 3 h post-dosing compared with
the control group (*p < 0.05).medium (DMEM) with 5% fetal calf serum (medium). Next, we
centrifuged the cells for 5 min at 4 8C, 1350 rpm, and dis-
carded the supernatant (centrifuge conditions were the same
for all experiments). We then resuspended the cell pellet in
2 mL of medium and quantified cells by use of 0.4% trypan
blue on a hemocytometer. Using the calculated live cell
number, we aliquoted cells to a concentration between 1
and 5  105 per FACS tube. All of the tubes were filled with
FACS buffer and centrifuged. We then added 20 mL of 2.4 G2
(an anti-FcgRII/III antibody that stops nonspecific binding;
obtained from BD Biosciences Clontech Labs, Palo Alto, CA,
USA), and incubated the tube for 15 min at room tempera-
ture. Ten microliters of the antibody or antibodies diluted to
the titration amount were added and incubated for 45 min at
4 8C. After incubation, we again added FACS buffer and
centrifuged. Finally, we added 300 mL of FACS buffer. Flow
cytometry was performed on a 3-detector BD FACScan or a 6-
detector BD LSR. The markers we examined were GR1 (neu-
trophils), CD11b (macrophages), CD3, CD4, and CD8 (Tcells).
Antibiotic susceptibility test
In order to ensure that S. pneumoniae was susceptible to
moxifloxacin, we sampled two broth solutions containing S.
pneumoniae. One solution contained 1 mg/mL of moxiflox-
acin, and the other served as a control. The broth solutions
were sampled at 0, 1, 2, 4, and 8 h. The samples were plated
on agar plates for 24 h at 37 8C. The CFUs were then counted
and the numbers of bacteria quantified.
Statistical analysis
Log conversion of the flow-cytometric and culture data was
performed for normalizing the data. Parametric two-tailed t-
tests were used. A p value <0.05 was considered to indicate
significance.
Results
We first compared treatment with moxifloxacin, azithromy-
cin, and placebo. On day 0, we infected mice with S. pneu-
moniae, and on day 1, we began administering the
treatments twice daily. On days 2—5, we euthanized mice
from each group. The control mice became infected and
remained infected through five days of observation. Treat-
ment with azithromycin reduced the amount of infection
within 24 hours of administration. By days 4 and 5 post-
infection, the bacteria were essentially eliminated. The
surprising result was a lack of effect of moxifloxacin on
the number of bacteria recovered (Figure 1).
We next performed experiments to determine why moxi-
floxacin was ineffective in our model. In the first experiment,
we evaluated the response of the mice at 1 h and 3 h post-
dosing. In this experiment, we evaluated the response at day
4 post-infection, looking at the time between the last doses
of moxifloxacin and harvesting of the tissue. Both timing
intervals showed a significant reduction in the bacterial
counts compared to control (Figure 2), but the results were
not equivalent to the effect of azithromycin. We also gath-
ered serum to measure drug levels. Moxifloxacin serum con-
centrations 1 h and 3 h post-dosing were 4.8 mg/mL and1.95 mg/mL, respectively. This demonstrated a rapid meta-
bolism of moxifloxacin in the mice.
To understand this rapid metabolism further, we measured
the serum levels after dosing. The serum from three mice was
collected at 0.5, 1, 2, and 4 h after a single gavage dose of
100 mg/kg moxifloxacin or 200 mg/kg azithromycin. Pharma-
cokinetic parameters for moxifloxacin and azithromycin are
shown in Table 1. The elimination of moxifloxacin was more
rapid than azithromycinwith aT1/2 of 1.4 h. Both azithromycin
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Table 1 Pharmacokinetic parameters of moxifloxacin and azithromycin in mouse serum
Drug Cmax (mg/mL) Tmax (h) T1/2 (h) AUC0—24 (mg h/mL) AUC0—24/MIC
Moxifloxacin 4.8 1 1.4 29.9 119.7
Azithromycin 8.9 0.5 1.6 50.4 201.6
Cmax, maximal concentration or activity observed; Tmax, time that the peak was observed; T1/2, half-life, was determined from the
elimination rate constant as calculated by linear regression analysis from Tmax to the last time point; AUC0—24, twice the AUC0—12 (area under
the time—concentration curves over 12 h); MIC, minimal inhibitory concentration.and moxifloxacin displayed a short lag in absorption before
reaching Tmax, with azithromycin attaining a peak concentra-
tion earlier than did moxifloxacin. The 24-h AUC/MIC ratios of
azithromycin and moxifloxacin were 201.6 and 119.7, respec-
tively. The serum AUC0—24 of azithromycin was 1.7-fold higher
than that of moxifloxacin. We also tested the susceptibility of
S. pneumoniae to moxifloxacin. The bacteria are sensitive to
1 mg/mL moxifloxacin (four times the MIC), but it takes about
4 h to produce effective killing (Figure 3).
Finally, we increased the dosing frequency of moxifloxacin
from 100-mg/kg twice daily to 100-mg/kg 6-hourly to try to
counter its high metabolic rate in mice. Azithromycin or
placebo was dosed as in the first experiment. We increased
the number of mice to seven in each group in order to
increase the statistical power. Moxifloxacin significantly
decreased the number of bacteria in the sinuses when com-
pared to the placebo control, although not to the level of
azithromycin (Figure 4).
Flow-cytometric analysis showed that there was an
increase in granulocytes, macrophages, and CD3-, CD4-,
and CD8-positive T cells in all infected sinusitis groups com-
pared to an uninfected group (wild type). Among the infected
groups, the granulocytes and macrophages (GR1) in the
azithromycin-treated group had a tendency to decrease
when the infection subsided, whereas the levels of CD3-,
CD4-, and CD8-positive Tcells were still high. In contrast, all
inflammatory cells were high in the persistently infected
groups. Interestingly, the inflammatory cells and CD3-,
CD4-, and CD8-positive T cells in the moxifloxacin-treated
groupwere at significantly higher levels than in the untreated
control group (Figure 5).Figure 3 Antibiotic susceptibility test demonstrated that
1 mg/mL moxifloxacin was effective in killing S. pneumoniae.Discussion
In man, both moxifloxacin and azithromycin are effective
agents in the treatment of acute bacterial rhinosinusitis
caused by susceptible strains of S. pneumoniae.7—18 In our
study, azithromycin significantly reduced the bacterial
counts in the sinus compared with placebo treatment. The
reduction in the bacteria recovered was accompanied by
faster resolution of the inflammation associated with the
infection. These results parallel the effect in man.
Surprisingly, moxifloxacin showed a minimal effect on
infection. We first eliminated the possibility that the strain
of S. pneumoniae studied was resistant to this antibiotic. We
next looked at the 24-h AUC/MIC and the peak/MIC ratios,
the primary pharmacokinetic/pharmacodynamic (PK/PD)
parameters used to determine the efficacy of the fluoroqui-
nolones in man. Animal survival studies in mice without
neutropenia, as well as clinical trials, all suggest that the
magnitude of the 24-h AUC/MIC ratio required for the effi-
cacy of fluoroquinolones or azithromycin against S. pneumo-
niae is in the 25—35 range.19—21 The AUC/MIC ratios for
moxifloxacin and azithromycin in our experiments were more
than 35, which is consistent with published reports. The factFigure 4 Bacterial counts from nasal lavage culture on day 5
post-infection in mice treated with 6-hourly doses of 100 mg/kg
moxifloxacin, 12-hourly doses of 200 mg/kg azithromycin, and
sterile water (control). Horizontal bar represents mean value.
The results showed that the bacterial numbers in the moxiflox-
acin-treated mice decreased significantly in comparison with the
control group (*p < 0.05), and in the azithromycin-treated mice
decreased significantly in comparison to both the moxifloxacin-
treated and control group (**p < 0.01).
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Figure 5 Numbers of total cells stained with GR1, CD11b, CD4, and CD8 at day 5 post-infection from sinus tissue of mice infected with
S. pneumoniae and treated with 6-hourly doses of 100 mg/kg moxifloxacin, 12-hourly doses of 200 mg/kg azithromycin, and sterile
water (control). Horizontal bar represents mean value. There was a significant increase in the numbers of GR1-, CD11b-, CD4-, and CD8-
stained cells in the moxifloxacin-treated mice in comparison with the azithromycin-treated (*p < 0.05) or control group (yp < 0.05).
Wild type (WT) mice received no treatment or infection.that the PK/PD goals were met, and bacterial clearance did
not occur, may suggest that moxifloxacin levels at the site of
infection are lower than in serum.
Siefert et al.,22 however, demonstrated high concentra-
tions of moxifloxacin in bile ducts and urine at 5 min and 1 h
after IV administration, indicating a rapid onset of excretion
in mice. The serum half-life of moxifloxacin in mice was
about 1—2 h,22—25 whereas azithromycin showed an extended
serum half-life of about 6 h in mice.17,18 Our results agree
with these findings and were further supported by the obser-
vation that, after we increased the frequency of dosing of
moxifloxacin, the outcome improved.
To explain the reduced effect ofmoxifloxacin, we hypothe-
sized that, because of the high metabolism in mice, the drug
may have killed some of the bacteria, but then, because it was
rapidlymetabolized, the S. pneumoniae repopulated the sinus
(S. pneumoniae doubled every 20 minutes).
Four hours post-dosing, the moxifloxacin serum level was
1.1 mg/mL, which was above the MIC of 0.25 mg/mL. It should
have a bactericidal effect at this level. This notion was
demonstrated by a serum inhibition assay in vitro, but it
took about 4 h to induce killing of the bacteria. The bacterial
counts in the sinuses 3 h post-dosing in vivo suggest that the
killing effect was not as great as in vitro. It is possible thatmoxifloxacin levels were lower in the mouse sinus mucosa
and extracellular fluid than in the serum. This would contrast
with the higher concentrations of moxifloxacin found in
human sinus tissues compared to the blood.22,26 Another
potential explanation for our observations is that the killing
effect of moxifloxacin is concentration-dependent10,11,27,28
and thus, due to high metabolic clearance, moxifloxacin had
a limited effect in our mouse model.
A further pharmacodynamic property exhibited by both
moxifloxacin and azithromycin is continued suppression of
anorganism’sgrowthafterantimicrobialexposure,27—29known
as the post-antibiotic effect (PAE). The PAEs for fluoroquino-
lones for both Gram-positive and Gram-negative isolates are
generally in the range of 1.5—2.5 h. Post-antibiotic subinhibi-
tory effects and post-antibiotic leukocyte enhancement have
also been described. These effects were not sufficient to
influence bacterial clearance in our model. Azithromycin has
a longer duration of subinhibitory concentrations, which may
have contributed to its PAEs and hence efficacy.30
Although we could not address our initial question about
comparing a bacteriostatic with a bactericidal drug, this
study shows the importance of the antimicrobial concentra-
tions at the site of infection as well as of the pharmacoki-
netics and pharmacodynamics of antimicrobial drugs. It also
406 T. Luxameechanporn et al.suggests that pharmacodynamic principles may not always
apply across species. Finally, our mousemodel proved helpful
in the exploration of the mechanisms of antimicrobials in the
treatment of acute bacterial rhinosinusitis.
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